Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Daishenning Granules (岱肾宁颗粒) is a traditional Dai medicine formulation developed by the Xishuangbanna Dai Nationality Autonomous Prefecture Dai Medical Hospital for the treatment of chronic kidney disease (CKD). It is a botanical-based therapy rooted in the traditional medical practices of the Dai ethnic group in China. The drug is currently being investigated in a multicenter, randomized, double-blind, placebo-controlled Phase IIa clinical trial to assess its safety and therapeutic efficacy in patients with CKD. As a complex herbal mixture, its pharmacological profile likely involves multiple active constituents targeting various pathways involved in renal protection and symptom management.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Daishenning Granules.